GlassScriptPhysician profile
Timothy J Luithle
NPI 1578581146
$2,232.27
in general payments reported to CMS, 2019-2025
38 companies · $277 in 2025
The $277 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $228 · 2020: $159 · 2021: $528 · 2022: $402 · 2023: $257 · 2024: $380 · 2025: $277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $914.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $914.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $362.12 | 2019-2023 | Jardiance |
| Novo Nordisk INC | $336.20 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $164.27 | 2021-2022 | |
| Mylan Specialty L.P. | $162.80 | 2019-2024 | Yupelri, Yupelri |
| Lilly USA, LLC | $132.98 | 2021-2024 | Jardiance, Zepbound, Mounjaro |
| Sanofi-Aventis U.S. LLC | $69.85 | 2020-2022 | |
| Phathom Pharmaceuticals, INC. | $64.42 | 2024-2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $58.99 | 2021-2024 | Eliquis |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $58.13 | 2025 | Caplyta |
| Abbvie INC. | $57.56 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $54.68 | 2022-2025 | |
| Boston Scientific Corporation | $50.05 | 2025 | General - Pain Management, Wavewriter Alpha Prime 16 |
| Acadia Pharmaceuticals INC | $48.74 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $45.53 | 2021-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Exact Sciences Corporation | $41.40 | 2023-2024 | Cologuard Collection Kit |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $37.41 | 2020 | |
| Pharmacosmos Therapeutics INC. | $37.14 | 2024-2025 | Monoferric |
| Bayer Healthcare Pharmaceuticals INC. | $36.63 | 2021 | |
| Lundbeck LLC | $35.74 | 2022-2024 | Rexulti |
| Nestle Healthcare Nutrition INC. | $30.55 | 2022-2023 | |
| Eisai INC. | $30.49 | 2021 | |
| Pfizer INC. | $29.86 | 2023 | |
| Alkermes, INC. | $29.00 | 2023 | Lybalvi, Aristada |
| Sanofi Pasteur INC. | $28.48 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $25.96 | 2020-2023 | Farxiga |
| Astellas Pharma US INC | $25.01 | 2019-2020 | |
| Amgen INC. | $19.77 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.14 | 2022 | |
| Abbott Laboratories | $17.92 | 2021 | |
| Genzyme Corporation | $17.73 | 2023 | |
| Ethicon US, LLC | $17.62 | 2021 | |
| Glaxosmithkline, LLC. | $14.97 | 2024 | Shingrix |
| Viatris Specialty LLC | $14.31 | 2025 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $13.81 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $12.63 | 2021 | |
| Esperion Therapeutics, INC. | $12.35 | 2020 | |
| Biogen, INC. | $11.14 | 2021 | |
| Dynavax Technologies Corporation | $6.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Luithle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.